The effect of osteopontin and osteopontin-derived peptides on preterm brain injury

Table 1 Doses used for drug administration ^a

	Intracerebroventricular administration			Intranasal administration
	rmOPN	N134–153	C154–198	rmOPN	T-OPN	N134–153
Dose (μg/pup)	0.05	0.2	0.5	1.2	1.2	30
Concentration (μg/μl)	0.025	0.1	0.25	0.2	0.2	5
Volume (μl)	2	2	2	6	6	6

^aC154–198, Osteopontin C-terminal residues 154 to 198; N134–153, Osteopontin N-terminal residues 134 to 153; rmOPN, Recombinant mouse osteopontin; T-OPN, Thrombin-cleaved osteopontin.

ISSN: 1742-2094